The DREAMS consortium brings together leading institutions from across the continent to develop data-driven, patient-derived models for therapeutic discovery in rare NMDs. UCL’s addition as the sole UK partner highlights the university’s longstanding commitment to collaborative European research. Neuromuscular diseases - which vary in severity and include conditions with life-threatening weakness impacting breathing muscles - affect approximately 150,000 people in the UK and around 14,000,000